ストックスクリーナーアプリを入手
10.03
4.39%
-0.46
アフターアワーズ：
10.04
0.010
+0.10%
前日終値:
$10.49
開ける：
$10.48
24時間の取引高:
1.35M
Relative Volume:
1.10
時価総額：
$592.92M
収益：
$106.47M
当期純損益:
$82.89M
株価収益率:
6.7153
EPS:
1.4936
ネットキャッシュフロー:
$-2.43M
1週間 パフォーマンス:
-8.90%
1か月 パフォーマンス:
-4.39%
6か月 パフォーマンス:
+16.63%
1年 パフォーマンス:
+17.04%
1日の値動き範囲:
$10.01
$10.73
1週間の範囲:
$10.01
$11.16
52週間の値動き範囲:
$7.16
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
10.03 | 620.12M | 106.47M | 82.89M | -2.43M | 1.4936 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 開始されました | BTIG Research | Buy |
| 2025-07-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-08 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 開始されました | Guggenheim | Buy |
| 2024-09-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-24 | 繰り返されました | Maxim Group | Buy |
| 2024-04-02 | 繰り返されました | Maxim Group | Buy |
| 2024-03-12 | 開始されました | William Blair | Outperform |
| 2023-03-17 | 開始されました | Maxim Group | Buy |
すべてを表示
Zevra Therapeutics Inc (ZVRA) 最新ニュース
Lightning eMotors Inc. (ZEV) - Minichart
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
ZVRA: AI-driven patient identification and global expansion fuel growth and pipeline acceleration - TradingView
Understanding Momentum Shifts in (ZVRA) - Stock Traders Daily
Zevra Therapeutics CEO to present company updates at H.C. Wainwright BioConnect Investor Conference - Traders Union
Zevra Therapeutics details arimoclomol and miglustat study findings for rare disease event - Traders Union
Did One-Off-Boosted Q1 Profits Just Shift Zevra Therapeutics' (ZVRA) Investment Narrative? - Sahm
A Look At Zevra Therapeutics (ZVRA) Valuation After Strong Earnings And SDX Portfolio Sale - Sahm
EDGAR Filing Documents for 0001434647-26-000021 - SEC.gov
Zevra Therapeutics (ZVRA) legal chief sells 1,794 shares under 10b5-1 plan - Stock Titan
Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear - Yahoo Finance
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference - The Manila Times
TradingKey - TradingKey
[144] ZEVRA THERAPEUTICS, INC. SEC Filing - Stock Titan
HC Wainwright Analysts Increase Earnings Estimates for ZVRA - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Earnings Call Highlights Growth Pivot - TipRanks
Number of shareholders of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView
Zevra Therapeutics (ZVRA) Is Up 8.2% After Debt-Free Turnaround And Rare Disease Refocus – What’s Changed - Sahm
Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
ZVRA Maintained by Guggenheim -- Price Target Raised to $25.00 - GuruFocus
Zevra Therapeutics price target raised to $25 from $23 at Guggenheim - TipRanks
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Investors Eye 107% Upside Potential - DirectorsTalk Interviews
Has Zevra Therapeutics (ZVRA) Finally Turned the Corner - Kavout
Zevra Therapeutics Q1 2026 Earnings: Revenue Surges 78% to $36.2M - IndexBox
Avoiding Lag: Real-Time Signals in (ZVRA) Movement - Stock Traders Daily
Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge? - Yahoo Finance
CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Zevra Therapeutics, Inc. Q1 2026 Financial Results and Forward-Looking Statements – Quarterly Report Highlights - Minichart
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call Transcript - Insider Monkey
Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Execution, Debt-Free Balance Sheet Support Upside with Price Target Maintained at $26 - TipRanks
Zevra Therapeutics Q1 Earnings Call Highlights - MarketBeat
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
MSN Money - MSN
Zevra outlines celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access - MSN
Earnings call transcript: Zevra Therapeutics Q1 2026 beats expectations with strong revenue growth By Investing.com - Investing.com Australia
Zevra Therapeutics (ZVRA) Q1 earnings and revenues surpass estimates - MSN
Zevra Therapeutics reports Q1 EPS 60c, consensus 8c - TipRanks
Zevra Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Zevra (ZVRA) Q1 2026 Earnings Call Transcript - AOL.com
ZVRA: Q1 2026 delivered 78% revenue growth, debt-free status, and expanded rare disease reach - TradingView
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Earnings call transcript: Zevra Therapeutics Q1 2026 beats expectations with strong revenue growth - Investing.com Nigeria
Zevra Therapeutics (ZVRA) turns profit, clears $63M debt with SDX sale - Stock Titan
Zevra Therapeutics (NASDAQ:ZVRA) Shares Surge After Blowout Q1 Earnings Beat - ChartMill
Zevra Therapeutics Inc. (ZVRA) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Zevra Therapeutics: Q1 Earnings Snapshot - Barchart.com
Q1 2026 Zevra Therapeutics Inc Earnings Call Transcript - GuruFocus
Debt-free after asset sale, Zevra ends quarter with $236.8M cash - Stock Titan
Zevra Reports First Quarter 2026 Financial Results and Corporate Update - The Manila Times
Zevra Therapeutics Inc (ZVRA) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):